Graph Therapeutics raises $5m to advance I&I pipeline
Austria’s Graph Therapeutics has raised $5m in new financing, bringing its total funding to more than $10m as it advances internal drug discovery programmes in inflammation and immunology built on its AI-enabled platform.
Why it matters: Graph is moving from platform development into proprietary drug discovery, a shift many TechBio companies are pursuing as they try to capture more value from AI-enabled biology.
Zoom in: Paris-based venture capital firm Daphni has joined its investor syndicate, alongside continued backing from SquareOne, Merantix Capital and NAVEC Investment Management.
How it works: Graph’s “lab-in-the-loop” perturbation approach uses primary patient cell samples and multi-omics data to decode immune dysfunction. The aim is to generate biological insights that can feed directly into drug discovery programmes, rather than relying only on retrospective or public datasets.
Backstory: Graph was founded by CEO Gregory Vladimer and CTO Robert Sehlke, who previously worked on AI-driven precision oncology at Allcyte. Allcyte was acquired by Exscientia in 2021.
Yes, but: Graph has not disclosed specific targets, lead assets or development timelines for its inflammation and immunology pipeline.
What’s next: The funding will help the company accelerate its internal pipeline across multiple inflammatory and immune-mediated disease indications while keeping open the option of strategic partnerships and out-licensing deals.
